This simple and low-cost treatment allows most patients to achieve an improved glycemic control – with minimal hypoglycemia – compared to insulin injections.[23] Pamela Bowman and colleagues studied a long-term follow-up of an international cohort of patients with neonatal diabetes due to KCNJ11 mutations who switched their treatments from insulin to sulfonylurea. The gene discussed is KCNJ11; the disease is diabetes mellitus.